Skip to main content
. 2021 Oct 20;13:764308. doi: 10.3389/fnagi.2021.764308

TABLE 2.

Correlations with PDQ-39 change.

No. r P
UPDRS-III off 40 0.152 0.348
UPDRS-III temor 40 0.314 0.049*
UPDRS-III rigidity 40 –0.030 0.855
UPDRS-III bradykenisia 40 0.021 0.898
UPDRS-III PIGD 40 0.134 0.408
UPDRS-III (OFF-60 min) 40 0.069 0.672
UPDRS-III temor (OFF-60 min) 26 0.494 0.010*
UPDRS-III rigidity (OFF-60 min) 39 –0.042 0.800
UPDRS-III bradykenisia (OFF-60 min) 40 0.027 0.871
UPDRS-III PIGD (OFF-60 min) 40 –0.046 0.777
UPDRS-III (OFF-120) 40 0.102 0.530
UPDRS-III temor (OFF-120) 26 0.483 0.012*
UPDRS-III rigidity (OFF-120) 39 0.100 0.546
UPDRS-III bradykenisia (OFF-12O) 40 0.027 0.871
UPDRS-III PIGD (OFF-120) 40 0.009 0.956
Age 40 0.188 0.246
LEDD (mg) 40 –0.144 0.377
MMSE 40 –0.393 0.012*
MOCA-B 40 –0.234 0.146
Duration 40 0.015 0.926
NMS 40 0.032 0.843
PDQ-39 40 0.392 0.012*
GDS 39 –0.016 0.921
BDI 40 0.084 0.606
SAS 40 0.143 0.378
SCPA-AUT 40 0.095 0.559
RBD 40 –0.113 0.488

MMSE, Mini-Mental State Exam; MoCA-B, Montreal Cognitive Assessment Basic; SAS, Self Rating Anxiety Scale; BDI, Beck Depression Inventory; GDS, Geriatric Depression Rating Scale; PDQ-39, 39-item Parkinson’s Disease Questionnaire; LEDD, levodopa equivalent dailydose; UPDRS-III, Unified Parkinson’s III total score; SCOPA-AUT, Parkinson’s disease autonomic dysfunction.

*P < 0.05.